2025-09-25 - Analysis Report
Okay, here's an analysis of Hims & Hers Health Inc. (HIMS) based on the data provided, presented in a report format.

## HIMS (Hims & Hers Health Inc.) Analysis Report

Hims & Hers Health Inc. is a telehealth company that offers personalized health and wellness solutions.

### 1. Performance Relative to S&P 500 (VOO)

*   **HIMS Cumulative Return:** 71.88%
*   **VOO Cumulative Return:** 44.03%
*   **Absolute Divergence (HIMS - VOO):** 27.85%
*   **Relative Divergence:** 63.3 (Indicates HIMS's performance is in the upper range of its historical divergence from VOO)

**Analysis:** HIMS has significantly outperformed the S&P 500 (VOO) based on cumulative returns. However, the relative divergence of 63.3 suggests that while HIMS is currently outperforming, this level of outperformance is not unprecedented in its historical performance relative to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
| :---------- | :----- | :----- | :----- | :---- | :----- |
| 2019-2021  | -36.0% | 78.9%  | -59.0% | 0.1   | 1.5    |
| 2020-2022  | -36.0% | 99.6%  | -32.0% | 0.1   | 1.4    |
| 2021-2023  | -77.0% | 100.0% | -88.0% | -0.0  | 2.0    |
| 2022-2024  | 68.0%  | 100.0% | 44.0%  | -0.0  | 5.5    |
| 2023-2025  | 98.0%  | 100.0% | 59.0%  | -0.1  | 12.2   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Highly variable, with significant negative growth in earlier periods, followed by strong positive growth more recently.
*   **MDD (Maximum Drawdown):** Consistently high MDD values indicate significant volatility and risk.
*   **Alpha:**  The Alpha is a way to evaluate how well an investment has performed when the risk is taken into account.  In recent years (2022-2025), the Alpha values are positive, indicating the investment is doing well, while in the past (2019-2023) the Alpha values are negative, indicating the investment is not doing well
*   **Beta:** Beta is a measure of how much the price of a stock moves relative to the overall stock market. A low Beta (2021-2025) means the stock is less volatile than the market, while a high Beta (2019-2023) means the stock is more volatile than the market.
*   **Cap(B):** Cap(B) measures a company's market capitalization, which is the total value of its outstanding shares. It gives investors an idea of the company's size compared to other companies.

### 2. Recent Stock Price Movement

*   **Current Price:** $53.89
*   **Last Market Data:**
    *   Price: $53.87
    *   Previous Close: $56.00
    *   Change: -$3.8 (Significant Drop)
*   **5-Day Moving Average:** 55.19
*   **20-Day Moving Average:** 49.76
*   **60-Day Moving Average:** 50.80

**Analysis:** The current price is below the 5-day moving average, suggesting short-term downward momentum. The price is above both the 20-day and 60-day moving averages, indicating a longer-term upward trend, although the recent price drop is concerning. The significant change in the last market data (-$3.8) signals a notable negative event impacting the stock.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.434 (Medium Risk)
*   **RSI:** 65.06 (Approaching overbought territory)
*   **PPO:** 1.89
*   **Hybrid Signal:** cash_0%_Buy 50% of cash (1 shares - Caution - MRI:0.42)
*   **Recent (20-Day) Relative Divergence Change:** 2.8 (+) (Short-term increase)
*   **Expected Return:** -7.4% (Long-term underperformance relative to S&P 500)

**Analysis:** The MRI indicates a medium risk level. The RSI is approaching overbought conditions, suggesting a potential pullback. The positive change in relative divergence over the last 20 days indicates recent outperformance, but the Hybrid Signal advises caution. The expected return is negative, suggesting that long-term investments may underperform the S&P 500.

### 4. Recent News & Significant Events

*   **Negative News:** Several articles highlight recent challenges, including a significant price dip, FDA concerns, and reasons for the stock trading lower.
*   **Positive News:** One article notes Hims & Hers' expansion of its care ecosystem through global and digital innovation.
*   **Insider Selling:** Recent SEC filings indicate that Hims & Hers Health insiders sold a significant number of shares.

**Analysis:** The news sentiment is mixed, but recent headlines lean toward the negative side. The negative news could be contributing to the recent price drop. Insider selling can sometimes be interpreted negatively by the market.

### 4-2. Analyst Opinions

*   **Consensus:** Hold
*   **Mean Rating:** 2.92 (~Hold)
*   **Number of Opinions:** 12
*   **Target Price (Avg/High/Low):** $47.42 / $85.00 / $25.00

**Analysis:** The analyst consensus is "Hold," suggesting a neutral outlook on the stock. The average target price of $47.42 is below the current price, indicating potential downside.

### 5. Recent Earnings Analysis

| Date       | EPS   | Revenue    |
| :---------- | :----- | :----- |
| 2025-08-04 | 0.19 | 0.54 B$  |
| 2025-05-05 | 0.22 | 0.59 B$  |
| 2024-11-04 | 0.35 | 0.40 B$  |
| 2024-08-05 | 0.06 | 0.32 B$  |
| 2025-08-04 | 0.06 | 0.32 B$  |

**Analysis:**
The company's EPS (Earnings Per Share) and revenue data over the past quarters show some fluctuations. The EPS seems to be improving, with a recent high of 0.35, but there have been some dips. Revenue has generally been on the rise, indicating growth in the company's top line.

### 6. Financial Information

| Quarter    | Revenue  | Profit Margin |
| :--------- | :------- | :-------------- |
| 2025-06-30 | $0.54B  | 76.39%          |
| 2025-03-31 | $0.59B  | 73.50%          |
| 2024-12-31 | $0.48B  | 76.81%          |
| 2024-09-30 | $0.40B  | 79.16%          |
| 2024-06-30 | $0.32B  | 81.30%          |

| Quarter    | Equity   | ROE     |
| :--------- | :------- | :------ |
| 2025-06-30 | $0.56B  | 7.55%   |
| 2025-03-31 | $0.55B  | 9.01%   |
| 2024-12-31 | $0.48B  | 5.46%   |
| 2024-09-30 | $0.44B  | 17.18%  |
| 2024-06-30 | $0.36B  | 3.67%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue has been steadily increasing, indicating growth in the company's sales. Profit margins are consistently high, suggesting efficient cost management and strong pricing power.
*   **Capital and Profitability:** Equity has also been increasing, reflecting the company's growing assets. ROE (Return on Equity) has fluctuated but remains positive, indicating the company's ability to generate profits from its shareholders' investments.

### 7. 종합 Conclusion

HIMS has shown strong growth and has outperformed the S&P 500 in terms of cumulative returns. However, recent news and market indicators suggest caution. The significant price drop, negative headlines, insider selling, and a "Hold" analyst consensus indicate potential risks. While the company's revenue and profit margins are strong, the negative expected return and approaching overbought RSI suggest that a pullback may be imminent.

**Recommendation:** Given the mixed signals, a neutral stance may be appropriate. Investors should closely monitor news and market indicators before making any investment decisions. The recent price drop and negative news warrant further investigation.
